Journal Article

DKFZ-2026-01352

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

Fizazi, K. ; Azad, A. A. ; Matsubara, N. ; Carles, J. ; Fay, A. P. ; De Giorgi, U. ; Joung, J. Y. ; Fong, P. C. C. ; Voog, E. ; Jones, R. J. ; Shore, N. D. ; Dunshee, C. ; Zschäbitz, S.DKFZ* ; Oldenburg, J. ; Ye, D. ; Lin, X. ; Kalac, M. ; Laird, A. D. ; Kennedy, D. ; Agarwal, N.

2026
Taylor & Francis London

Keyword(s): Clinical trials ; genetics ; homologous recombination repair ; metastasis ; prostate cancer ; urologic/prostate

Note: #NCTZFB9# / epub

---

Contributing Institute(s):

1. Koordinierungsstelle NCT Heidelberg (HD02)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---